Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26

Mary A. Fletcher, Xiao R. Zeng, Kevin Maher et al. · 2010

Read Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 by Mary A. Fletcher, Xiao R. Zeng, Kevin Maher et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010817.txt.

Description

Mary Fletcher and colleagues evaluated blood markers for chronic fatigue syndrome, in PLOS ONE in 2010. The syndrome brings crushing fatigue without a clear lab test. Two immune signs had recurred in earlier work: weak natural killer cell killing, and raised levels of a surface marker called CD26 on lymphocytes. Neither had been validated as a biomarker.

Measured afresh in patients and controls, both signs differed as earlier work suggested. The team weighed them against strict biomarker standards. Having any objective measure would change life for patients whose illness is often doubted. The study moves the pair from hints toward tests, while noting the validation still to come.

Catalog record

CREATORMary A. Fletcher, Xiao R. Zeng, Kevin Maher et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010817

Browse the full library · About the Tower of Babel